- Home
- PULM vs ENLV Comparison
PULM vs ENLV Comparison
Compare PULM & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- ENLV
- Stock Information
- Founded
- PULM 2003
- ENLV 2005
- Country
- PULM United States
- ENLV Israel
- Employees
- PULM N/A
- ENLV N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- ENLV Health Care
- Exchange
- PULM Nasdaq
- ENLV Nasdaq
- Market Cap
- PULM 20.5M
- ENLV 23.7M
- IPO Year
- PULM N/A
- ENLV 1995
- Fundamental
- Price
- PULM $4.71
- ENLV $1.82
- Analyst Decision
- PULM
- ENLV Strong Buy
- Analyst Count
- PULM 0
- ENLV 2
- Target Price
- PULM N/A
- ENLV $10.00
- AVG Volume (30 Days)
- PULM 10.4K
- ENLV 555.5K
- Earning Date
- PULM 08-06-2025
- ENLV 08-29-2025
- Dividend Yield
- PULM N/A
- ENLV N/A
- EPS Growth
- PULM N/A
- ENLV N/A
- EPS
- PULM N/A
- ENLV N/A
- Revenue
- PULM $369,000.00
- ENLV N/A
- Revenue This Year
- PULM N/A
- ENLV N/A
- Revenue Next Year
- PULM $134.88
- ENLV N/A
- P/E Ratio
- PULM N/A
- ENLV N/A
- Revenue Growth
- PULM N/A
- ENLV N/A
- 52 Week Low
- PULM $1.78
- ENLV $0.81
- 52 Week High
- PULM $10.40
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- PULM 32.51
- ENLV 76.81
- Support Level
- PULM $4.65
- ENLV $1.31
- Resistance Level
- PULM $5.09
- ENLV $1.66
- Average True Range (ATR)
- PULM 0.28
- ENLV 0.18
- MACD
- PULM -0.01
- ENLV 0.04
- Stochastic Oscillator
- PULM 5.38
- ENLV 65.85
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.